The Experts below are selected from a list of 60 Experts worldwide ranked by ideXlab platform
Kong Jin-sheng - One of the best experts on this subject based on the ideXlab platform.
-
Design and Implementation of ARCE Risk Treatment Plan Measurement Model
Computer Engineering, 2011Co-Authors: Kong Jin-shengAbstract:This paper proposes a novel model called ARCE(Assets Risk Value Control Measures Effectiveness).Correctness of the model is proved theoretically.A quantitative ARCE index system is proposed,with the input of organization's information security assets Risk value and control measure implemented,and the output of Risk Treatment Plan effectiveness matrix through intermediate variable matrix.The implementation process of the model includes Risk assessment,Risk Treatment,quantitative measurement,security event management and report five modules.It introduces the implementation pseudo code and flow of application for ARCE model,gives an example of implementing this model in some organization.The superiorities of implementing this model are measuring Risk Treatment Plan's effectiveness accurately,using preventive measures to improve organizations' security.
Anggi Rifa Pradana - One of the best experts on this subject based on the ideXlab platform.
-
design of information security Risk management using iso iec 27005 and nist sp 800 30 revision 1 a case study at communication data applications of xyz institute
International Conference on Information Technology Systems and Innovation, 2017Co-Authors: Hermawan Setiawan, Fandi Aditya Putra, Anggi Rifa PradanaAbstract:Information security is a priority for the organization. Information can be carried as critical assets, because it's advocated a national security. Communication data applications in the XYZ Institute advocated national security. However, it has amounted vulnerabilities and threats at their information systems and networks. With vulnerabilities and threat which give impact, appears an information security Risk for their organization. This causes the organization needs information security Risk management process for communication data applications in XYZ Institute. To Implement design of information security Risk management for communication data applications in XYZ Institute, we used ISO 27005 framework and NIST SP 800-30 revision 1 as a guideline to Risk assessment, and ISO 27002 as reference to development Risk Treatment Plan. The result of this research is how to implementation a design of information security Risk management at communication data applications in XYZ Institute.
-
Design of information security Risk management using ISO/IEC 27005 and NIST SP 800-30 revision 1: A case study at communication data applications of XYZ institute
2017 International Conference on Information Technology Systems and Innovation (ICITSI), 2017Co-Authors: Hermawan Setiawan, Fandi Aditya Putra, Anggi Rifa PradanaAbstract:Information security is a priority for the organization. Information can be carried as critical assets, because it's advocated a national security. Communication data applications in the XYZ Institute advocated national security. However, it has amounted vulnerabilities and threats at their information systems and networks. With vulnerabilities and threat which give impact, appears an information security Risk for their organization. This causes the organization needs information security Risk management process for communication data applications in XYZ Institute. To Implement design of information security Risk management for communication data applications in XYZ Institute, we used ISO 27005 framework and NIST SP 800-30 revision 1 as a guideline to Risk assessment, and ISO 27002 as reference to development Risk Treatment Plan. The result of this research is how to implementation a design of information security Risk management at communication data applications in XYZ Institute.
Hermawan Setiawan - One of the best experts on this subject based on the ideXlab platform.
-
design of information security Risk management using iso iec 27005 and nist sp 800 30 revision 1 a case study at communication data applications of xyz institute
International Conference on Information Technology Systems and Innovation, 2017Co-Authors: Hermawan Setiawan, Fandi Aditya Putra, Anggi Rifa PradanaAbstract:Information security is a priority for the organization. Information can be carried as critical assets, because it's advocated a national security. Communication data applications in the XYZ Institute advocated national security. However, it has amounted vulnerabilities and threats at their information systems and networks. With vulnerabilities and threat which give impact, appears an information security Risk for their organization. This causes the organization needs information security Risk management process for communication data applications in XYZ Institute. To Implement design of information security Risk management for communication data applications in XYZ Institute, we used ISO 27005 framework and NIST SP 800-30 revision 1 as a guideline to Risk assessment, and ISO 27002 as reference to development Risk Treatment Plan. The result of this research is how to implementation a design of information security Risk management at communication data applications in XYZ Institute.
-
Design of information security Risk management using ISO/IEC 27005 and NIST SP 800-30 revision 1: A case study at communication data applications of XYZ institute
2017 International Conference on Information Technology Systems and Innovation (ICITSI), 2017Co-Authors: Hermawan Setiawan, Fandi Aditya Putra, Anggi Rifa PradanaAbstract:Information security is a priority for the organization. Information can be carried as critical assets, because it's advocated a national security. Communication data applications in the XYZ Institute advocated national security. However, it has amounted vulnerabilities and threats at their information systems and networks. With vulnerabilities and threat which give impact, appears an information security Risk for their organization. This causes the organization needs information security Risk management process for communication data applications in XYZ Institute. To Implement design of information security Risk management for communication data applications in XYZ Institute, we used ISO 27005 framework and NIST SP 800-30 revision 1 as a guideline to Risk assessment, and ISO 27002 as reference to development Risk Treatment Plan. The result of this research is how to implementation a design of information security Risk management at communication data applications in XYZ Institute.
Vincenzo Pavone - One of the best experts on this subject based on the ideXlab platform.
-
Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi
Blood, 2013Co-Authors: Annalisa Chiappella, Silvia Franceschetti, Alessia Castellino, Angelo Michele Carella, Ileana Baldi, Manuela Zanni, Anna Marina Liberati, Michele Spina, Alessandra Tucci, Vincenzo PavoneAbstract:Introduction The standard Treatment for elderly untreated diffuse large B-cell lymphoma (DLBCL) is RCHOP21, however up to 40% of patients experienced failures. Lenalidomide showed activity in heavily pretreated DLBCL and in vivo and in vitro data demonstrated a synergism with rituximab. In the phase I trial REAL07 (Chiappella et al, Haematol 2013), FIL demonstrated that the association of LRCHOP21 was feasible in elderly untreated DLBCL and identified 15 mg lenalidomide from day 1 to day 14 as the maximum tolerated dose in combination with RCHOP21. Patients and methods. The phase II trial REAL07 was designed based on Simon's two stage design to demonstrate an improvement of overall response rate (ORR) of 15% in LRCHOP21 compared to 70% of standard RCHOP21. Secondary endpoints were progression-free survival (PFS), overall survival (OS), event-free survival (EFS) and to correlate outcome with cell of origin (COO) profile. Response was evaluated according to 2007 Cheson criteria. Inclusion criteria were: age 60-80 FIT at the comprehensive geriatric assessment; untreated CD20+ DLBCL; Ann Arbor stage II/III/IV; international prognostic index (IPI) at low-intermediate/intermediate-high/high (LI/IH/H) Risk. Treatment Plan was: RCHOP21 plus 15 mg lenalidomide from day 1 to 14 for 6 courses. All cases were centrally reviewed by expert pathologist; COO profile analysis was conducted with immunohistochemistry according to Hans' algorithm and with gene expression profile (DASL assay). Results. From April 2010 to May 2011, 49 patients were enrolled. Clinical characteristics were: median age 69 years (range 61-80); stage III/IV 43 (88%), IPI IH/H 30 (61%). At the end of 6 LRCHOP21, ORR was 92%. Complete remissions (CR) were 42 (86%) and partial remission 3 (6%); 3 patients (6%) did not respond and one (2%) died for homicide. At a median follow-up of 28 months, 2-year OS was 92% (95% CI: 79-97), 2-year PFS was 80% (95% CI: 64-89) and 2-years EFS was 70% (95% CI: 55-81); 2-year PFS for IPI LI was 89% (95% CI: 62-97) and for IPI IH 76% (95% CI: 47-90) and for IPI H 72% (95% CI: 36-90). Hematological and extra-hematological toxicities were mild, with no grade IV extra-hematological events and no toxic deaths during Treatment. Of the 294 Planned courses of LRCHOP21, 277 (94%) were administered; median dose of lenalidomide delivered was 1185 mg (94% of the Planned dose); at least 90% of the Planned dose of each drug was administered in 91% of the RCHOP21 courses. Median interval time between RCHOP21 courses was 21 days (range 19-48). All 49 cases underwent central pathology review and diagnosis of DLBCL was confirmed. Regarding COO analysis, tissue block or stained slides were collected in 40/49 (82%), of which 32 were adequate for analysis. At the time of this abstract, COO analysis was reported according to immunohistochemistry data; DASL analysis is ongoing. Clinical characteristics between germinal center (GCB, 16 patients) and non-GCB (16 patients) were superimposable, excepted for a majority of H IPI Risk in non-GCB group (p 0.067). ORR for GCB and non-GCB were 88% (CR 81%) and 88% (CR 88%), respectively. At a median follow-up of 28 months, 2-year PFS was 71% (95% CI: 40-88) in GCB-group and 2-years PFS was 81% (95% CI: 51-93) in non-GCB-group ([Figure 1][1]). Conclusions. In conclusion, LRCHOP21 is effective, also in poor Risk patients, namely in non-GCB subgroup. These encouraging data warrant a future phase III randomized trial comparing LRCHOP21 vs. RCHOP21 in untreated non-GCB DLBCL. ![Figure][2] Disclosures: Off Label Use: lenalidomide in first line DLBCL is off lable. drug provided free by Celgene. Vitolo: Roche: Speakers Bureau; Celgene: Speakers Bureau; Takeda: Speakers Bureau. [1]: #F1 [2]: pending:yes
-
Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)
Blood, 2012Co-Authors: Annalisa Chiappella, Silvia Franceschetti, Alessia Castellino, Angelo Michele Carella, Ileana Baldi, Manuela Zanni, Anna Marina Liberati, Michele Spina, Chiara Bottelli, Vincenzo PavoneAbstract:Abstract 903 Introduction. R-CHOP21 is the standard Treatment for untreated elderly DLBCL, however up to 40% of patients fail. There is a need to improve the efficacy of R-CHOP21; an option may be the addition of novel drugs in first line induction therapy. Lenalidomide has a complex mechanism of action as immunemodulation, antiangiogenesis, restoration of immunesynapses and direct antitumor effects. Lenalidomide monotherapy exhibits significant activity in patients with relapsed aggressive B-cell NHL and has in vitro synergy with rituximab and cytotoxic therapy. This rationale prompted FIL to conduct a prospective multicenter dose finding phase I-II trial aimed at evaluating toxicity and activity of lenalidomide plus R-CHOP21 (LR-CHOP21) in elderly untreated DLBCL (NCT00907348). In the dose-finding phase I study, 21 patients were enrolled, and 15 mg lenalidomide from day 1 to day 14 was identified as the maximum tolerated dose (MTD) in combination with R-CHOP21 (Vitolo, Ann Oncol 2011;22(4):331a). Patients and Methods. Based on the phase I results, 15 mg of lenalidomide in combination to R-CHOP21 was tested in a phase II study. Phase II was designed according to Simon9s two stage design; primary endpoint was an improvement of overall response rate (ORR) of 15% in LR-CHOP21 compared to 70% of standard R-CHOP21 and the study would be considered of interest if at least 16/23 in step 1 and 39/49 in step 2 responses occurred. Response was evaluated according to 2007 Cheson criteria. PET scan was mandatory at the end of the Treatment; patients in partial remission (PR) who underwent radiotherapy were considered as failure in progression free survival (PFS) analysis. Inclusion criteria were: age 60–80 FIT at the comprehensive geriatric assessment; untreated CD20+ DLBCL; Ann Arbor stage II/III/IV; IPI at LI/IH/H Risk. Treatment Plan was: R-CHOP21 plus 15 mg lenalidomide from day 1 to 14 for 6 courses. Mandatory supportive care included: GCSF or PegGCSF, cotrimoxazole as Pneumocystis Jiroveci prophylaxis and low molecular weight heparin or low dose aspirin as deep venous thrombosis prophylaxis. Results. From April 2010 to May 2011, 49 patients were enrolled in the phase II study including 9 patients treated at the MTD during phase I. Clinical characteristics were: median age 69 years (range 61–80); stage III/IV 43 (88%), performance status >1 31 (63%), IPI IH/H 30 (61%). The step-1 of the trial showed an ORR of 22/23. At the end of 6 LR-CHOP21, ORR was 45/49 (92%). Complete remissions (CR) were 42 (86%) and PR 3 (6%); 3 patients (6%) did not respond and one (2%) died for violent death. At a median follow-up of 18 months, overall survival (OS) was 94% (95% CI: 82–98) and PFS was 75% (95% CI: 57–86). (Figure 1). Of the 294 Planned courses of LR-CHOP21, 277 (94%) were administered, of which 221 (75%) with lenalidomide as Planned, 40 (14%) with dose and/or day reduction and 16 (5%) without lenalidomide. Median dose of lenalidomide delivered in 49 patients was 1185 mg (IQR 900–1260), i.e. 94% of the Planned dose (1260 mg). The most frequent cause of lenalidomide reduction or withdrawal was neutropenia. At least 90% of the Planned dose of doxorubicine, cyclophosphamide and vincristine were administered, in: 91%, 95% and 83% of the R-CHOP21 courses, respectively. Median interval time between R-CHOP21 courses was 21 days (range 19–48). Hematological toxicity was mild: grade III/IV thrombocytopenia occurred in 13% of courses, anemia in 5% and neutropenia in 33%, with only 4% of febrile neutropenia. No grade IV extra-hematological toxicities were observed. Grade III non-hematological toxicities were reported in 7 patients: cardiologic, gastroenteric and renal in one patient respectively, grade III neurological toxicities, sensory and motorial neuropathy in two, thromboembolic event in one not receiving anti-thrombotic prophylaxis, and skin rash in one. No toxic deaths occurred during Treatment. One patient died three months off therapy while in CR, due to aeromonas hydrophila sepsis and multi-organ failure. Conclusions. The addition of 15 mg lenalidomide on days 1–14 to R-CHOP21 is safe, feasible and effective in elderly untreated DLBCL. The primary objective of the phase II study was met, with 92% of ORR of which 86% CR and promising PFS rates. The addition of lenalidomide did not impair the administration of R-CHOP21. Based on these data, the efficacy of LR-CHOP21 needs to be investigated in a large phase III randomized trial in elderly DLBCL. Disclosures: Off Label Use: Trial partially supported by a research grant by Celgene. Lenalidomide was provided free by Celgene. The use of Lenalidomide is off-label in untreated DLBCL. Dreyling:Roche: Membership on an entity9s Board of Directors or advisory committees. Vitolo:Roche: Membership on an entity9s Board of Directors or advisory committees.
Alan Calder - One of the best experts on this subject based on the ideXlab platform.
-
Information Security Based on ISO 27001/ISO 17799: A Management Guide
2006Co-Authors: Alan CalderAbstract:Introduction Information security Background to the standards Use of the standards Certification process Overview of ISO 27001 Summary of changes from BS 7799-2:2002 ISO 27000 series in future Integration with other management systems Record contraol Management responsibility The PDCA cycle Scope definition Risk assessment Risk Treatment Plan The statement of applicability Monitor & review the ISMS Maintain the ISMS Annex A control areas ISO 27001 & CobiT ISO 27001, ITIL & ISO 20000
-
information security based on iso 27001 iso 17799 a management guide
2006Co-Authors: Alan CalderAbstract:Introduction Information security Background to the standards Use of the standards Certification process Overview of ISO 27001 Summary of changes from BS 7799-2:2002 ISO 27000 series in future Integration with other management systems Record contraol Management responsibility The PDCA cycle Scope definition Risk assessment Risk Treatment Plan The statement of applicability Monitor & review the ISMS Maintain the ISMS Annex A control areas ISO 27001 & CobiT ISO 27001, ITIL & ISO 20000
